172@29@17@246!~!172@29@0@53!~!|news|india|fda-approved-drug-teicoplanin-found-more-effective-in-treating-covid-19-virus-iit-delhi-research-5893721.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to Moneycontrol Pro and get 365 bonus InterMiles! Use Code: INTERMILES
you are here: HomeNewsIndia
Last Updated : Sep 28, 2020 12:33 PM IST | Source: PTI

FDA approved drug 'Teicoplanin' found more effective in treating COVID -19 virus: IIT Delhi research

The research by the institute's Kusuma School of Biological Science screened an assemblage of 23 approved drugs, which have shown leads towards being therapeutic options for coronavirus.

PTI

Clinically approved drug "Teicoplanin" is a potential therapeutic option against COVID-19 and can be ten times more effective than several drugs being currently used, a research by Indian Institute of Technology (IIT), Delhi has found.

The research by the institute's Kusuma School of Biological Science screened an assemblage of 23 approved drugs, which have shown leads towards being therapeutic options for coronavirus.

Close

"While the effect of Teicoplanin was compared with other important drugs in use, Teicoplanin was found to be 10-20 fold more effective than the chief drugs being used against SARS-CoV-2, such as Lopinavir and Hydroxychloroquine in our laboratory conditions," said Ashok Patel, Professor at IIT Delhi.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Patel, who led the research was also assisted by Dr Pradeep Sharma from AIIMS. The research has also been published in the International Journal of Biological Macromolecules.

Teicoplanin is an FDA-approved glycopeptide antibiotic, which is regularly used for treating Gram-positive bacterial infections with low toxicity profile in humans.

"Recently, there has been a clinical study carried out with Teicoplanin at Sapienza University in Rome. However, a more detailed clinical investigation is required on a large cohort, in different stages mild, moderate and critically ill patients to conclude the definite role of Teicoplanin against COVID-19," Patel said.

Globally, over 3.2 crore people have been infected with COVID-19, and the total number of deaths from the deadly virus now stands at over 9.80 lakh.

India's coronavirus tally galloped past 60 lakh on Monday with 82,170 new cases, while the number of recoveries surged to 50.17 lakh after 74,893 more people recuperated, the Health Ministry said.

The death toll from the pathogen climbed to 95,542 with 1,039 more deaths. There are 9,62,640 active cases of the coronavirus disease (COVID-19), comprising 15.85 per cent of the caseload, according to the ministry data.
First Published on Sep 28, 2020 12:02 pm
Sections